CounterX TherapeuticsCounterX TherapeuticsCounterX Therapeutics
  • Home
  • About
  • Platform
  • Pipeline
    • CTRX 101
    • Publications
  • News
  • Team
  • Contact

Search Posts

About Us

Lorem ipsum dolor sit amet, consectetur adipisc glelit, sed do eiusmod tempor incididunt .ut labo et dolore magna aliqua.

Blog Categories

  • Media (2)
  • Press Release (3)
  • Publications (9)

Recent Posts

March 10, 2026

Puget Sound Business Journal: CounterX Therapeutics inks licensing deal for opioid abuse treatments

by Jacques Bouchy
March 9, 2026

CounterX Therapeutics Executes Exclusive Licensing Agreement for Portfolio of Novel Monoclonal Antibody and Vaccine Candidates Targeting Fentanyl and Opioid Overdose

by Jacques Bouchy
March 2, 2026

CounterX Therapeutics Announces Formation of Scientific Advisory Board with Leading Experts in Substance Use Disorders

by Jacques Bouchy
December 3, 2025

Wired: A Fentanyl Vaccine Is About to Get its First Major Test

by Jacques Bouchy
October 29, 2025

CounterX Therapeutics Announces Publication Demonstrating CTRX-101, an Anti-Fentanyl Monoclonal Antibody Therapy, Reverses Fentanyl-Induced Overdose in Preclinical Model

by Jacques Bouchy
Post placeholder image
October 10, 2025

An anti-fentanyl monoclonal antibody reverses fentanyl-induced apnea in pigs

by pjwcreative

Recent Comments

No comments to show.

Tags

March 10, 2026 in Media

Puget Sound Business Journal: CounterX Therapeutics inks licensing deal for opioid abuse treatments

Jacques Bouchy 1 Like Post Comments Off on Puget Sound Business Journal: CounterX Therapeutics inks licensing deal for opioid abuse treatments

PRESS RELEASE CounterX Therapeutics Executes Exclusive Licensing Agreement for Portfolio of Novel Monoclonal Antibody and Vaccine Candidates Targeting Fentanyl and Opioid Overdose SEATTLE ...

Read More
  • Follow Us
  • Contact Us

©2025 CounterX Therapeutics. All Rights Reserved.